Search

AEM-28

AEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]

Diazolidinylurea

Clofazimine

treatments such as [rifampicin] and [isoniazid]. … Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy.

Paraldehyde

Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties.

Tilactase

[A27172] The beta-D-galactosidase us a large monomeric multi-domain enzyme of 985 residues that presents a catalytic (alpha/beta)8-barrel domain. … Tilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal.

Febuxostat

The manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … Febuxostat is a non-purine xanthine oxidase (XO) inhibitor.

Miglustat

Miglustat was first developed as an anti-HIV agent in the 1990s. … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.

Recombinant stabilized RSV A prefusion F antigen

[L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555] … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

Astemizole

Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms.

Moxonidine

It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.